Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lantheus Holdings (NQ: LNTH )

81.63 -1.24 (-1.50%)
Streaming Delayed Price Updated: 11:01 AM EDT, May 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lantheus Holdings

< Previous 1 2 3 4 5 6 7 8 9 Next >
Lantheus to Present Piflufolastat F 18 Data at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus Announces Acquisition of Cerveau Technologies, Inc., Expanding Imaging Pipeline into Alzheimer’s Disease
MK-6240 is an F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer’s Disease 
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus to Present at the J.P. Morgan 2023 Healthcare Conference
From Lantheus Holdings, Inc.
Via GlobeNewswire
Looking Into Lantheus Holdings's Return On Capital Employed
Via Benzinga
Lantheus Holdings: Q3 Earnings Insights
Lantheus Holdings (NASDAQ:LNTH) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Lantheus Announces Closing of Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003 with POINT Biopharma
From Lantheus Holdings, Inc.
Via GlobeNewswire
Cramer's Take On This Stock Up 48% Year-To-Date: 'I Would Not Want To Come In At This Level'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Royal Caribbean Cruises Ltd (NYSE: RCL) is an "excellent" company. 
Via Benzinga
Lantheus Grants Rights for the Use of its Microbubbles to SonoThera for its Ultrasound-Guided Nonviral Gene Therapy Platform
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus Holdings, Inc. Announces Pricing of Offering of $500 Million Convertible Senior Notes due 2027
From Lantheus Holdings, Inc.
Via GlobeNewswire
Why Iovance Biotherapeutics Shares Are Trading Higher By Around 19%? Here Are 40 Stocks Moving In Monday's Mid-Day Session
Gainers Winc, Inc. (NYSE: WBEV) rose 88.5% to $0.3901 after dropping over 23% on Friday. Winc, last month, posted a Q3 loss of $0.33 per share. 
Via Benzinga
VF Corp, Verve Therapeutics And Some Other Big Stocks Moving Lower On Monday
U.S. stocks traded lower, with the Dow Jones dropping over 200 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Lantheus Holdings, Inc. Announces Proposed Offering of $500 Million Convertible Senior Notes due 2027
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus Holdings Stock Showing Market Leadership; Earns 94 RS Rating
Lantheus Holdings stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, rising from 90 to 94. 
Via Investor's Business Daily
Lantheus Announces Appointment of Amanda Morgan as Senior Vice President, Commercial
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus Announces the Approval of DEFINITY® (Perflutren Lipid Microsphere) by China’s NMPA
DEFINITY is the leading diagnostic ultrasound enhancing agent for patients with suboptimal echocardiograms 
From Lantheus Holdings, Inc.
Via GlobeNewswire
7 Index Funds to Buy to Retire a Millionaire
Although the market shows signs of improvement, the waters are still choppy enough for investors to focus on index funds to buy. 
Via InvestorPlace
3 Stocks That Could Be the Next Big M&A Targets
These three potential M&A deals run the gamut from very possible to very unlikely, despite the benefits of a transaction getting done. 
Via InvestorPlace
These 3 Stocks Are Crushing the Market. Wall Street Thinks They Can Soar at Least 78% Higher.
The good times could keep on rolling for these big winners. 
Via The Motley Fool
PDS Biotechnology To Rally Around 129%? Here Are 5 Other Price Target Changes For Tuesday
Via Benzinga
Lantheus-POINT Biopharma Ink Strategic Collaboration For Cancer Programs
Via Benzinga
Lantheus and POINT Biopharma Announce Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003
From Lantheus Holdings, Inc.
Via GlobeNewswire
S&P 500 Component DexCom Set For Further Price, Earnings Growth
Glucose monitor maker DexCom surged 19% after its Q3 report, and shares are holding those gains. Wall Street sees more growth ahead in 2023. 
Via MarketBeat
Topics Stocks
Exposures US Equities
Lantheus to Present at the Jefferies London Healthcare Conference
From Lantheus Holdings, Inc.
Via GlobeNewswire
Jim Cramer Says Tesla Has 'The Worst Chart I've Ever Seen': Is He Still A Believer?
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Antero Resources Corporation (NYSE: AR) is very, very cheap…and "I’m not going to say anything bad about it." 
Via Benzinga
Kellogg, Palo Alto Networks, Roku And Other Big Losers From Thursday
U.S. stocks closed lower on Thursday, with the Dow Jones dropping more than 100 points. Here is the list of some big stocks recording losses in the previous session. 
Via Benzinga
Lantheus Reports Third Quarter 2022 Financial Results
From Lantheus Holdings, Inc.
Via GlobeNewswire
MarketBeat: Week in Review 10/24-10/28
Stocks finished the week on a bullish note, and the MarketBeat analysts continue to guide you to the stocks and stories that are moving the market 
Via MarketBeat
Topics Economy Electric Vehicles
Exposures Economy Electric Vehicles Interest Rates
Can Mid-Cap Lantheus Continue its 2022 Outperformance?
Mid-cap Lantheus Holdings has been on a revenue growth spurt boosted by a new product called Pylarify, which helps detect prostate cancer in an imaging test. 
Via MarketBeat
Topics ETFs Initial Public Offering
Exposures Securities Market
Lantheus to Host Third Quarter 2022 Earnings Conference Call and Webcast on November 3, 2022, at 8:00 a.m. Eastern Time
From Lantheus Holdings, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.